{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'NAMES AND ADRESSES OF:', \"MONITORING TEAM'S REPRESENTATIVE\", 'Name:', 'Address:', 'Tel:', 'Fax:', 'E-mail', 'SPONSOR', 'Name:', 'Genzyme Corporation', 'Address:', '50 Binney Street', 'Cambridge, MA 02142, USA', 'Property of the Sanofi Group - strictly confidential', '6']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'PROTOCOL SYNOPSIS', 'Protocol Title', 'ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with', 'Hemophilia A or B, with Inhibitory Antibodies to Factor VIII or IX', 'Product Name', 'Fitusiran (INN); SAR439774 (formerly Alnylam ALN-AT3SC)', 'Indication', 'Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and adolescent', '(12 years old) hemophilia A or B patients', 'Phase', '3', 'Study centers', 'The study will be conducted at approximately 100 clinical study centers worldwide.', 'Objectives', 'Primary', 'To evaluate the efficacy of fitusiran compared to on-demand treatment with BPAs (bypassing', 'agents), as determined by the frequency of bleeding episodes.', 'Secondary', 'To evaluate the efficacy of fitusiran compared to on-demand treatment with BPAs,', 'as determined by:', '- The frequency of spontaneous bleeding episodes', '- The frequency of joint bleeding episodes', '-', 'Health-related quality of life (HRQOL) in patients > >17 years of age', 'To determine the frequency of bleeding episodes during the onset period', 'To determine the safety and tolerability of fitusiran', 'Exploratory', 'To evaluate the effects of fitusiran as compared to on-demand treatment with BPAs on the', 'following patient-reported outcomes:', '-', 'Patient satisfaction with treatment', '-', 'Patient activity', '-', 'HRQOL in adolescents (12 to <17 years of age)', 'To characterize the pharmacodynamic (PD) effect, pharmacokinetics (PK), and', 'immunogenicity of fitusiran', 'To evaluate the effects of fitusiran as compared to on-demand treatment with BPAs on the', 'Property of the Sanofi Group - strictly confidential', '7']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'total weight-adjusted consumption of BPAs', 'To evaluate the effects of fitusiran as compared to on-demand treatment with BPAs on joint', 'status', 'To evaluate the effects of fitusiran as compared to on-demand treatment with BPAs on patient', 'resource use.', 'Endpoints', 'Primary', 'Annualized Bleeding Rate (ABR) in the efficacy period', 'Secondary', 'ABR in the treatment period', 'Annualized spontaneous bleeding rate in the efficacy period', 'Annualized joint bleeding rate in the efficacy period', 'Change in Hemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL) physical', 'health score and total score in the treatment period', 'ABR in the onset period', 'Exploratory', 'Change in the following in the treatment period:', '- Treatment Satisfaction Questionnaire for Medication (TSQM) domain scores', '- Hemophilia Activities List (HAL) scores', '- Pediatric HAL (pedHAL) scores', '- EuroQol-5 dimension (EQ-5D) scores', '- Hemophilia Quality of Life Questionnaire for children and adolescents (Haemo-QOL)', 'scores', '-', 'Hemophilia Joint Health Score (HJHS)', 'Number of target joint bleeding episodes', 'Incidence and titer of antidrug antibodies to fitusiran in the fitusiran treatment arm', 'Antithrombin (AT) activity level over time', 'Thrombin generation over time', 'Fitusiran plasma levels', 'Annualized weight-adjusted consumption of BPAs', 'Change in patient resource use (eg, work/school attendance, visits to doctor/hospital)', 'Safety', 'Incidence, severity, seriousness, and relatedness of adverse events (AEs)', 'Property of the Sanofi Group - strictly confidential', '8']\n\n###\n\n", "completion": "END"}